Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Eur Ann Allergy Clin Immunol ; 48(4): 137-44, 2016 Jul.
Article En | MEDLINE | ID: mdl-27425169

BACKGROUND: The term "breakthrough reactions" designates repeated hypersensitivity reactions to iodinated contrast media (ICM) despite premedication with glucocorticoids and antihistamines. We aimed to retrospectively evaluate the rate of positive skin test (STs) in our cohort of patients with previous breakthrough reactions to different ICMs. METHODS: A series of 35 patients, who experienced at least one breakthrough reaction to ICM and who underwent STs within 6 months from the reaction were studied, and results were compared to a control group of patients with a first hypersensitivity reaction occurred without premedication. Skin prick tests (SPT), intradermal tests (IDT) and patch tests (PT) at different dilutions, with a set of three to four ICM were performed. RESULTS: Of the 35 patients with prior breakthrough reactions, 57% had an immediate reaction (IR) and 43% had a non-immediate reaction (NIR). Patients who experienced the first hypersensitivity IR or NIR, later had one or more breakthrough IR or NIR, respectively. Overall, 29% (10/35) of patients with prior breakthrough reactions resulted positive to STs compared to 57% (16/28) of the control group (p < 0.05). No significant difference in allergy history, age, sex, other clinical / demographic features nor chronic use of ACE-inhibitor, beta-blockers or NSAIDs was observed. CONCLUSION: This preliminary finding suggests that patients with prior breakthrough reactions have significantly lower immunologically proven ICM reactions (positive STs) if compared to non-breakthrough patients. According to that, a considerable number of breakthrough reactions seems to be non-allergic hypersensitivity reactions or reactions which could be mostly prevented by a proper, well-timed skin testing. Larger prospective studies are needed to confirm these results, with a more careful analysis of patients' risk factors, a laboratory assessment that includes an in vitro allergy diagnostics, and hopefully a drug provocation test for selected cases.


Contrast Media/administration & dosage , Drug Hypersensitivity/diagnosis , Hypersensitivity, Delayed/diagnosis , Hypersensitivity, Immediate/diagnosis , Intradermal Tests , Patch Tests , Adult , Aged , Drug Hypersensitivity/immunology , Drug Hypersensitivity/prevention & control , Female , Glucocorticoids/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/immunology , Hypersensitivity, Delayed/prevention & control , Hypersensitivity, Immediate/chemically induced , Hypersensitivity, Immediate/immunology , Hypersensitivity, Immediate/prevention & control , Male , Middle Aged , Predictive Value of Tests , Recurrence , Reproducibility of Results , Retrospective Studies , Risk Factors
2.
Eur Ann Allergy Clin Immunol ; 47(3): 77-85, 2015 May.
Article En | MEDLINE | ID: mdl-25951145

The purpose of the present work is to evaluate the efficacy of an approach that combines clinical history, skin tests results, and premedication, in preventing recurrent hypersensitivity reactions to iodinated contrast media (ICM). Skin Prick tests, Intradermal tests, and Patch tests were performed in 36 patients with a previous reaction to ICM. All patients underwent a second contrast enhanced radiological procedure with an alternative ICM selected on the basis of the proposed approach. After alternative ICM re-injection, only one patient presented a mild NIR. The proposed algorithm, validated in clinical settings where repeated radiological exams are needed, offers a safe and practical approach for protecting patients from recurrent hypersensitivity reactions to ICM.


Contrast Media/adverse effects , Drug Hypersensitivity/prevention & control , Iodine Compounds/adverse effects , Skin Tests , Adult , Aged , Algorithms , Critical Pathways , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/etiology , Female , Humans , Intradermal Tests , Male , Middle Aged , Predictive Value of Tests , Recurrence , Reproducibility of Results , Risk Factors , Young Adult
3.
Int J Immunopathol Pharmacol ; 26(3): 801-6, 2013.
Article En | MEDLINE | ID: mdl-24067481

Buckwheat allergy is considered a rare food allergy outside of Asia. In Europe, buckwheat has been described mainly as a hidden allergen. Data on the prevalence of buckwheat hypersensitivity in non-Asian countries is very poor. The aim of this multicenter study was to evaluate the prevalence of buckwheat sensitization and its association with other sensitizations among patients referred to allergy clinics in different geographic areas of Italy. All patients referred to 18 Italian allergy clinics from February through April 2011 were included in the study and evaluated for sensitization to buckwheat and other allergens depending on their clinical history. A total of 1,954 patients were included in the study and 61.3 percent of them were atopic. Mean prevalence of buckwheat sensitization was 3.6 percent with significant difference between Northern (4.5 percent), Central (2.2 percent) and Southern (2.8 percent) regions. This is, to our knowledge, the largest epidemiological survey on buckwheat allergy reported outside of Asia. Buckwheat is an emerging allergen in Italy, being more frequently associated to sensitization in Northern regions.


Allergens , Fagopyrum/adverse effects , Food Hypersensitivity/epidemiology , Adult , Female , Food Hypersensitivity/diagnosis , Food Hypersensitivity/immunology , Humans , Italy/epidemiology , Male , Middle Aged , Predictive Value of Tests , Prevalence , Referral and Consultation , Skin Tests , Young Adult
...